Lacosamide Macleods (Lacosamide)

Lacosamide is used as an adjunctive antiepileptic agent that targets focal seizure activity in various forms of epilepsy.

• Partial‑onset seizures: reduces the frequency of seizures when combined with other antiepileptic medications, providing better seizure control.
• Focal epilepsy: enhances overall seizure management as an add‑on therapy, helping patients achieve more stable neurological function.
• Refractory epilepsy: may be employed in patients whose seizures are not adequately controlled by existing treatments, offering an additional therapeutic option.
• Adjunctive therapy for partial‑onset seizures in adults: improves quality of life by decreasing seizure burden.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyper‑excitability. It also binds to collapsin response mediator protein‑2 (CRMP‑2), which may modulate axonal transport and neuronal differentiation. By these actions, the drug diminishes the propagation of epileptic discharges without affecting normal neuronal firing, contributing to seizure control when used as add‑on therapy.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or weak.
• Nausea: upset stomach often accompanied by an urge to vomit.
• Headache: mild to moderate pain in the head.
• Blurred vision: temporary loss of visual clarity.
• Diplopia: double vision, especially during rapid eye movements.

Serious or Rare Side Effects

• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Cardiac arrhythmia: irregular heart rhythm, including atrioventricular block.
• QT prolongation: lengthening of the heart’s electrical cycle.
• Severe skin reactions: rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.
• Hypersensitivity: swelling, hives, or anaphylactic response.
• Respiratory depression: slowed breathing, especially with CNS depressants.

When prescribing Lacosamide, clinicians should consider several safety precautions to minimize risk.

• Monitor cardiac function: obtain baseline ECG and observe for conduction abnormalities.
• Assess renal function: adjust dose in patients with impaired clearance.
• Avoid abrupt discontinuation: taper gradually to prevent seizure worsening.
• Use caution in hepatic impairment: consider dose reduction if liver function is compromised.
• Pregnancy: risk category unknown; discuss potential benefits and risks with the patient.
• Check for drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
• Co‑administration with other sodium‑channel blockers (e.g., lamotrigine, valproate): may increase risk of CNS depression.

Moderate Interactions (Monitor Closely)

• Other antiepileptic drugs: may require dose adjustments based on therapeutic response.
• Alcohol: can enhance dizziness and sedation.
• QT‑prolonging agents: combined use may increase risk of cardiac arrhythmias.
• Concomitant use with antihypertensives: may potentiate blood pressure lowering effects.